Research Paper Volume 12, Issue 24 pp 25101—25119
Could microtubule inhibitors be the best choice of therapy in gastric cancer with high immune activity: mutant DYNC1H1 as a biomarker
- 1 Department of Medical Oncology, The First Hospital of China Medical University, Shenyang 110001, China
- 2 Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang 110001, China
- 3 Liaoning Province Clinical Research Center for Cancer, Shenyang 110001, China
- 4 Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, Shenyang 110001, China
- 5 Department of Medical Oncology, Shenyang Fifth People Hospital, Tiexi District, Shenyang 110001, China
- 6 Laboratory I of Cancer Institute, The First Hospital of China Medical University, Shenyang 110001, China
Received: January 13, 2020 Accepted: August 27, 2020 Published: November 20, 2020
https://doi.org/10.18632/aging.104084How to Cite
Abstract
Immune checkpoint blockade (ICB) has achieved unprecedented breakthroughs in various cancers, including gastric cancer (GC) with high immune activity (MSI-H or TMB-H), yet clinical benefits from ICB were moderate. Here we aimed to identify the most appropriate drugs which can improve outcomes in GC. We firstly compared MSI-H and TMB-H GC samples with normal samples in TCGA-STAD cohort, respectively. After that, Connectivity Map database repurposed nine candidate drugs (CMap score < -90). Then, microtubule inhibitors (MTIs) were screened as the significant candidate drugs with their representative gene sets strongly enriched (p < 0.05) via GSEA. GDSC database validated higher activities of some MTIs in GC cells with MSI-H and TMB-H (p < 0.05). Furthermore, some MTIs activities were positively associated with mutant Dynein Cytoplasmic 1 Heavy Chain 1 (DYNC1H1) (p < 0.05) based on NCI-60 cancer cell line panel. DYNC1H1 was high frequently alteration in GC and was positively associated with TMB-H and MSI-H. Mutant DYNC1H1 may be accompanied with down-regulation of MTIs-related genes in GC or change the binding pocket to sensitize MTIs. Overall, this study suggested that some MTIs may be the best candidate drugs to treat GC with high immune activity, especially patients with DYNC1H1 mutated.
Abbreviations
ICB: immune checkpoint blockade; GC: gastric cancer; STAD: stomach adenocarcinoma; TCGA: The Cancer Genome Atlas; MSI-H: high microsatellite instability; TMB-H: high tumor mutational burden; CMap: Connectivity Map; MTIs: microtubule inhibitors; DYNC1H1: Dynein Cytoplasmic 1 Heavy Chain 1; DEGs: differentially expressed genes; GSEA: gene sets enrichment analysis; PPI: protein-protein interaction; NCI-60: National Cancer Institute 60; GDSC: genomics of drug sensitivity in cancer; IC50: inhibitory concentration; GI50: growth inhibition; UCEC: Uterine Corpus Endometrial Carcinoma.